Welcome to our dedicated page for Enlivex Therapeutics news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex Therapeutics stock.
Enlivex Therapeutics Ltd (ENLV) is a clinical-stage biopharmaceutical company pioneering macrophage-reprogramming therapies through its lead candidate Allocetra. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and strategic developments across its pipeline targeting immune dysregulation.
Access primary-source ENLV news including clinical trial results, research collaborations, and regulatory filings related to Allocetra's development in sepsis, osteoarthritis, and autoimmune conditions. Our curated news collection enables efficient tracking of the company's progress in creating off-the-shelf cell therapies designed to restore immune homeostasis.
Key updates include advancements in Phase I/II trials, manufacturing partnerships, and peer-reviewed data publications. Bookmark this page for direct access to ENLV's official press releases and objective third-party analysis of their innovative approach to immune rebalancing therapies.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its participation in the ARDS Drug Development Summit on July 15, 2021. The Company will present AllocetraTM, a promising therapy for acute respiratory distress syndrome (ARDS), a condition with limited effective treatments. The inaugural summit aims to address drug development challenges for both COVID-19 and non-COVID-19 related ARDS. AllocetraTM is designed to reprogram macrophages to restore immune balance, potentially serving life-threatening conditions.
Enlivex Therapeutics has announced the initiation of design and construction for a new cGMP manufacturing plant in Israel, aimed at expanding production capacity for its immunotherapy product Allocetra. This facility, initially planned to be 17,000 square feet with potential expansion to 21,500 square feet, will support ongoing and future clinical trials, along with initial commercial production upon regulatory approvals. CEO Oren Hershkovitz emphasized that this expansion is crucial for advancing clinical readiness for sepsis and COVID-19 treatments.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced participation in A.G.P.’s Virtual Summer Healthcare Symposium on June 17, 2021. The event includes 1-on-1 virtual meetings with investors interested in the company’s management team.
Enlivex is developing Allocetra™ as a universal cell therapy aimed at reprogramming macrophages to restore their homeostatic state, potentially addressing various serious conditions, including solid cancers and COVID-19.
Enlivex Therapeutics (Nasdaq: ENLV) announced the issuance of European patent No. 3,258,943 for AllocetraTM, enhancing its intellectual property portfolio. This patent covers a combination immune therapy aimed at controlling cytokine storms associated with CAR-T therapies for cancer. CEO Oren Hershkovitz expressed satisfaction with the patent grant in Europe, reinforcing the potential of Allocetra in cancer treatment. Allocetra is designed to reprogram macrophages to address severe conditions like sepsis, COVID-19, and solid tumors.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced its participation in the Jefferies 2021 Virtual Healthcare Conference on June 4, 2021, at 10:00 EDT. The presentation will be accessible via the conference website.
Enlivex is focused on Allocetra™, a universal cell therapy aimed at reprogramming macrophages to restore immune system balance. This therapy has potential applications in treating solid cancers, sepsis, and COVID-19, targeting unmet medical needs with an innovative immunotherapeutic approach.
Enlivex Therapeutics (Nasdaq: ENLV) announced the issuance of Canadian Patent No. 2,893,962 for its immunotherapy product candidate AllocetraTM, providing additional protection for its pharmaceutical compositions and manufacturing methods. The patent enhances Enlivex's intellectual property portfolio, contributing to its focus on treating life-threatening diseases such as sepsis, COVID-19, and solid tumors. CEO Oren Hershkovitz emphasized the importance of this patent in supporting their clinical development efforts aimed at addressing significant unmet medical needs.
Enlivex Therapeutics has received a $1.1 million grant from the Israel Innovation Authority, bringing its total non-dilutive funding to approximately $6.6 million for clinical trials and product development. This funding supports Enlivex's ongoing Phase IIb clinical trial of Allocetra for treating organ dysfunctions related to sepsis. Allocetra is designed to reprogram macrophages into their homeostatic state to combat severe diseases, including sepsis and COVID-19, addressing unmet medical needs.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has partnered with Yale Cancer Center to explore the efficacy of Allocetra™ in combination with immune checkpoint inhibitors to target hard-to-treat solid tumors. This collaboration aims to conduct pre-clinical studies assessing the synergies between Allocetra™ and approved therapies. Enlivex recently reported positive Phase Ib and II results for Allocetra™ in COVID-19 and plans to initiate a Phase IIb study in sepsis. This strategic alliance emphasizes the potential of Allocetra™ to rebalance anti-tumor macrophages in the tumor microenvironment.
Enlivex Therapeutics (Nasdaq: ENLV), a clinical-stage immunotherapy company, announced its participation in two upcoming investor conferences. Management will join the 2nd Annual European Healthtech CEO Forum on March 9, focusing on patient care during the pandemic. They will also present at the H.C. Wainwright Global Life Sciences Conference on March 10, addressing innovative allogeneic cell-based immunotherapy in oncology. Enlivex is developing Allocetra™, a cell therapy aimed at reprogramming macrophages to their homeostatic state, potentially aiding in severe diseases like COVID-19 and solid cancers.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced that the Japan Patent Office has granted a notice of allowance for a new patent covering AllocetraTM, its macrophage reprogramming immunotherapy product. This patent, titled “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment,” will protect certain methods and uses of AllocetraTM in conjunction with CAR-T therapies in Japan. The company anticipates the patent will be officially issued in Q2 2021, further strengthening its intellectual property portfolio.